A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

September 3, 2010

AIDS Cure Research: North Carolina Scientist Study Cancer Drug

The search for an AIDS cure is about to take a new step as scientists begin human studies involving an existing but little-used cancer drug from Merck, reports Bloomberg News. David Margolis, MD, and his colleagues from the University of North Carolina in Chapel Hill hope the drug will take them further down the path of finally purging all HIV out of someone’s body, ultimately achieving a cure.

The drug, called Zolinza (vorinostat), is part of a family of drugs known as histone deacetylase (HDAC) inhibitors. Previous research found that Zolinza was able to flush out HIV that typically sits latent in resting CD4 cells in the body, waiting to bring an infection roaring back to life if an HIV-positive person stops taking his or her antiretroviral (ARV) drugs.

Margolis and a top researcher at Merck, Daria Hazuda, PhD, concede that the drug might be too toxic to ever make it as an HIV therapy, but they hope that Margolis’s proof-of-concept study will tell them whether they’re on the right track.

“It’s really all about trying to move the field ahead,” Margolis told Bloomberg News. “We don’t expect to cure anybody, but we expect to really show whether it can work the way we think it does in people—or not.”

The report goes on to detail the promise of HDAC inhibitors and then looks at a number of companies, including Gilead and Tibotec as well as Merck, that have “cure” research programs.

“Everybody has now come to the conclusion that it’s going to take a combination of different approaches,” Hazuda said. “Because there are HDAC inhibitors that are already licensed to treat other diseases, they may provide at least an anchor upon which to build a first-generation regimen.”

Some harbor lingering skepticism about ever eradicating HIV from the body, but Margolis remains undeterred.

“I’m 51,” Margolis said. “I’m not doing this because I think that I can’t succeed before I die.”

Search: HDAC inhibitors, histone deacetylase, Zolinza, vorinostat, David Margolis, reservoir, latent, cure, Daria Hazuda, Merck, cancer, Gilead, Tibotec


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (3 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    Hillcrester
    Ramona
    California


    RyGuy00
    New York
    New York


    youngbloodlatino
    Columbia
    Maryland


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.